title: GPR55: Metabolic Help or Hindrance?
abstract: Since the discovery of the lysophospholipid-sensitive receptor GPR55, hopes have been raised that targeting this G protein-coupled receptor (GPCR) may represent a novel approach for the treatment of metabolic disorders. We discuss conflicting evidence surrounding GPR55 physiology and highlight its potential as a novel target for the treatment of obesity and diabetes.
authors.affiliation: Centre for Cognitive and Neural Systems, University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK. Electronic address: chris.henstridge@ed.ac.uk.
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Henstridge
authors.affiliation: Screening, Profiling, and Mechanistic Biology, GlaxoSmithKline, Medicines Research Centre, Stevenage SG12NY, UK.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Brown
authors.affiliation: Department of Incretin Biology, Novo Nordisk A/S, Novo Nordisk Park, 2760 Måløv, Denmark.
authors.forename: Maria
authors.initials: M
authors.lastname: Waldhoer
mesh_terms: D000818:Animals; D006801:Humans; D008659:Metabolic Diseases / Q000235:genetics / Q000378:metabolism*; D009765:Obesity / Q000235:genetics / Q000378:metabolism; D043882:Receptors, Cannabinoid; D043562:Receptors, G-Protein-Coupled / Q000235:genetics / Q000378:metabolism*
chemical_list: C524885:GPR55 protein, human; D043882:Receptors, Cannabinoid; D043562:Receptors, G-Protein-Coupled
keywords: GPR55; LPI; diabetes; metabolism; obesity